Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and EP547 to multiple clinical milestones SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing. The financing was co-led by NEA, A

MEMPHIS, Tenn., Nov. 22, 2022 /PRNewswire/ -- Indigo Agriculture today announced the commercial launch of the industry's first biological fungicide based on the microbe Kosakonia cowanii, giving farmers a leg up on the 2023 growing season. Initially registered and announced by the company in April 2022, biotrinsic X19 is the first fungicide in Indigo's line of biological seed treatments, which offers farmers the flexibility to design effective crop protection plans based on t